{"organizations": [], "uuid": "7e9e48bb4718c2139eb151cb4d97b3aacbf5f684", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-arvinas-announces-research-collabo/brief-arvinas-announces-research-collaboration-and-license-agreement-with-pfizer-inc-idUSFWN1OY0NY", "country": "US", "domain_rank": 408, "title": "BRIEF-Arvinas announces research collaboration and license agreement with Pfizer Inc", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.91, "site_type": "news", "published": "2018-01-04T13:13:00.000+02:00", "replies_count": 0, "uuid": "7e9e48bb4718c2139eb151cb4d97b3aacbf5f684"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-arvinas-announces-research-collabo/brief-arvinas-announces-research-collaboration-and-license-agreement-with-pfizer-inc-idUSFWN1OY0NY", "ord_in_thread": 0, "title": "BRIEF-Arvinas announces research collaboration and license agreement with Pfizer Inc", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 5:13 AM / Updated an hour ago BRIEF-Arvinas announces research collaboration and license agreement with Pfizer Inc Reuters Staff 1 Min Read \nJan 4 (Reuters) - Arvinas LLC: \n* ARVINAS ANNOUNCES RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC. FOR THE DISCOVERY AND DEVELOPMENT OF PROTEIN DEGRADATION DRUG CANDIDATES \n* ANNOUNCED A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC​ \n* ARVINAS SAYS MAY RECEIVE UP TO $830 MILLION IN UPFRONT AND POTENTIAL DEVELOPMENT AND COMMERCIALIZATION MILESTONE PAYMENTS UPON ACHIEVEMENT OF SPECIFIED MILESTONES​ \n* ‍CO MAY BE ENTITLED TO RECEIVE TIERED ROYALTIES BASED ON GLOBAL PRODUCT SALES ON ANY PRODUCTS THAT MAY RESULT FROM COLLABORATION​ Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-04T13:13:00.000+02:00", "crawled": "2018-01-04T08:02:06.026+02:00", "highlightTitle": ""}